|Articles|July 9, 2019

U.S. Research Launches Initiative to Help Treat Dementia

The Synexus HealthyMinds Registry is seeking 30,000 U.S. participants, age 50 or older, who do not have dementia, for a five-year study examining the lifestyle and genetic risk factors impacting cognitive function over time. Supporting researchers’ goal of identifying ways to prevent and treat Alzheimer’s disease and other forms of dementia.

Learn more about the initiative and how to participate here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

November 2nd, 2026

ACT Brief: Community Research Policy Needs, Walmart Trial Centers, and Psoriatic Arthritis Approval

In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.

© peshkova - © peshkova - stock.adobe.com

October 30th, 2026

Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas

The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.

October 30th, 2026

What Needs to Happen Beyond the Clinical Trial Modernization Act

In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.

October 30th, 2026

ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance

In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.

October 29th, 2026

Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda

In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.

October 29th, 2026

How Embedding Research Into Routine Community Care Changes Who Gets Access

In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.

October 29th, 2026

ACT Brief: Community Trial Access Technology, RBQM Infrastructure, and Digital Clone Use Cases

In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.

© putilov_denis - © putilov_denis - stock.adobe.com

October 28th, 2026

Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without

The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.

U.S. Research Launches Initiative to Help Treat Dementia

Related to this article

Trending on Applied Clinical Trials Online

What Needs to Happen Beyond the Clinical Trial Modernization Act

Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda

Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas

Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without

ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance